**Table 2** Comparison of characteristics between patients with and without bleeds in the rivaroxaban group

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Patients without bleed** | **Patients with bleed** | **p-value** |
| Patients, *N* | 68 | 29 |  |
|  |  |  |  |
| Peak plasma concentration (ng/mL), median (IQR)  Trough plasma concentration (ng/mL), median (IQR) | 180.98 (109.12 – 271.98)  29.26 (13.54 – 52.61) | 182.58 (149.90 – 267.06)  33.50 (19.53 – 43.21) | 0.457  0.828 |
| Peak concentration (Classes), n (%)  Class I  Class II – IV  Trough concentration (Classes), n (%)  Class I  Class II – IV | 28 (41.2)  40 (58.8)  37 (54.4)  31 (45.6) | 8 (27.6)  21 (72.4)  17 (58.6)  12 (41.4) | 0.254  0.824 |
|  |  |  |  |
| Gender, n (%)  Male  Female  Age, median (IQR)  BMI (kg/m2), median (IQR)  CrCl (mL/min), median (IQR)a  Previous SSE, n (%)  Previous major bleed, n (%) | 28 (84.8)  5 (15.2)  66.0 (59.0 – 70.0)  27.4 (24.4 – 31.2)  70.8 (57.7 – 85.8)  15 (22.1)  6 (8.8) | 23 (79.3)  6 (20.7)  64.0 (57.5 – 69.0)  25.1 (22.6 – 28.7)  61.5 (49.4 – 79.8)  2 (6.9)  0 (0.0) | 0.336  0.484  0.059\*  **0.047\*\***  0.086\*  0.174 |
|  |  |  |  |
| Antiplatelets, n (%)  Amiodarone, n (%)  Angiotensin receptor blockers, n (%)b  Losartan  Telmisartan  Valsartan  Combined total  HMG-CoA reductase inhibitors, n (%)c  Atorvastatin  Rosuvastatin  Simvastatin  Combined total | 8 (11.8)  5 (7.4)  5 (7.4)  3 (4.4)  8 (11.8)  16 (23.5)  43 (63.2)  0 (0.0)  4 (5.9)  47 (69.1) | 5 (17.2)  3 (10.3)  2 (6.9)  0 (0.0)  2 (6.9)  4 (13.8)  14 (48.3)  2 (6.9)  7 (24.1)  23 (79.3) | 0.521  0.693  1.000  0.548  0.718  0.412  1.000  0.069\*  **0.024**\*\*  0.336 |
| Abbreviations: *IQR* inter-quartile range, *BMI* body mass index, *CrCl* creatinine clearance, *SSE* stroke and systemic embolism, *HMG-CoA* 3-hydroxy-3-methylglutaryl coenzyme A.  \*\*p-value < 0.05.  \*p-value < 0.10.  a There were missing data for this variable in the dataset. Median (IQR) for this variable is presented based on available data (Without bleed: *N* = 66; With bleed: *N* = 28).  b No use of any angiotensin receptor blocker was considered the reference group.  c No use of any HMG-CoA reductase inhibitor was considered the reference group. | | | |